EFFECTIVE Act

Hozzl · 2024-03-13T11:23:51Z

Explore the details of Senate Bill 607 EFFECTIVE Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/13/2024, 11:23 AM

Congressional Summary of S 607

Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 607

Bill S 607 is currently in the status of Bill Introduced since March 1, 2023. Bill S 607 was introduced during Congress 118 and was introduced to the Senate on March 1, 2023. Bill S 607's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of March 1, 2023

Bipartisan Support of Bill S 607

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 607

Primary Policy Focus

Health

Alternate Title(s) of Bill S 607

EFFECTIVE Act

Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act

A bill to allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.